Subscribe
eye-istock-489756064-mark_kuiken-
Mark_Kuiken / iStockphoto.com
26 September 2017Americas

Native American tribe aims to dismiss Allergan patent IPRs

The Saint Regis Mohawk Tribe has attempted to dismiss inter partes reviews (IPR) brought by Mylan.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Tech companies have their say on Allergan-tribe deal at PTAB
4 December 2017   The Computer & Communications Industry Association (CCIA) and the Association for Accessible Medicines (AAM) have urged the Patent Trial and Appeal Board (PTAB) to dismiss a Native American tribe’s attempt to shut down a series of inter partes reviews (IPRs).
Americas
Native American tribe not entitled to sovereign immunity: PTAB
26 February 2018   The Patent Trial and Appeal Board rejected the Saint Regis Mohawk Tribe’s attempt to dismiss inter partes reviews related to dry-eye treatment Restasis late last week.
Americas
The future of sovereign immunity deals after Allergan ruling
1 March 2018   Late last week, the Patent Trial and Appeal Board rejected a Native American tribe’s attempt to dismiss inter partes reviews based on the tribe’s sovereign immunity claims.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Tech companies have their say on Allergan-tribe deal at PTAB
4 December 2017   The Computer & Communications Industry Association (CCIA) and the Association for Accessible Medicines (AAM) have urged the Patent Trial and Appeal Board (PTAB) to dismiss a Native American tribe’s attempt to shut down a series of inter partes reviews (IPRs).
Americas
Native American tribe not entitled to sovereign immunity: PTAB
26 February 2018   The Patent Trial and Appeal Board rejected the Saint Regis Mohawk Tribe’s attempt to dismiss inter partes reviews related to dry-eye treatment Restasis late last week.
Americas
The future of sovereign immunity deals after Allergan ruling
1 March 2018   Late last week, the Patent Trial and Appeal Board rejected a Native American tribe’s attempt to dismiss inter partes reviews based on the tribe’s sovereign immunity claims.

More on this story

Americas
Tech companies have their say on Allergan-tribe deal at PTAB
4 December 2017   The Computer & Communications Industry Association (CCIA) and the Association for Accessible Medicines (AAM) have urged the Patent Trial and Appeal Board (PTAB) to dismiss a Native American tribe’s attempt to shut down a series of inter partes reviews (IPRs).
Americas
Native American tribe not entitled to sovereign immunity: PTAB
26 February 2018   The Patent Trial and Appeal Board rejected the Saint Regis Mohawk Tribe’s attempt to dismiss inter partes reviews related to dry-eye treatment Restasis late last week.
Americas
The future of sovereign immunity deals after Allergan ruling
1 March 2018   Late last week, the Patent Trial and Appeal Board rejected a Native American tribe’s attempt to dismiss inter partes reviews based on the tribe’s sovereign immunity claims.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?